Theralink
The Theralink platform
The Theralink Assay
Request RPPA Analyte List
RPPA Clinical Publications
RPPA Research Publications
RPPA Technical Publications
Biopharmas
Explore Targets
Build-a-Pathway
Theralink → Medical Advisory Board
LANCE LIOTTA, M.D., PH.D.
Medical Advisory Board Chairman
Dr. Lance Liotta has served as Co-Director and Co-Founder of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University since 2005. Prior to this appointment, Dr. Liotta served as Chief of the Laboratory of Pathology, NCI, Deputy Director of NIH, Co-Director of the NCI/FDA Clinical Proteomics Program, and Director of the Anatomic Pathology Residency Program.
At the NIH he went on to investigate the process of tumor invasion and metastasis at the molecular level (MMP2, and TIMP2). He was the first to describe tumor cell invasion of the basement membrane (3-step hypothesis) and the role of tumor cell pseudopodia in tumor cell invasion.
Dr. Liotta has invented and patented, along with his laboratory co-inventors, transformative technologies in the fields of diagnostics, cancer molecular therapeutics, Laser Capture Microdissection, and proteomics (Reverse Phase Protein Microarrays, Biomarker Harvesting Nanoparticles, preservation chemistries for molecular analysis, and "protein painting" for drug target mapping) that have been used to make broad discoveries in cancer biology, and diagnostics, and therapeutics. The Laser Capture Microdissection prototype is in the Smithsonian Collection.
He is a co-founder of Theranostics Health and Ceres Nanosciences. Dr. Liotta has more than 100 issued or allowed patents and more than 700 publications. He is an ISI highly cited investigator and the recipient of numerous awards for biomedical research including the 2015 Outstanding Virginia Faculty Award (SCHEV), the Flemming Award for Cancer Research, the Warner-Lambert Parke Davis Award, and the Surgeon General's Medallion. He is Board Certified in Anatomic Pathology and is Medical Director of the GMU CAP/CLIA certified clinical proteomics Lab.
Contact us for help?
Theralink Technologies intends to be a market leader in precision medicine for more effective cancer treatments
Theralink® Technologies Issues Letter to Shareholders
Theralink® Technologies Announces Partnership with Perthera to Facilitate and Accelerate Access to its Unique Phosphoprotein and Drug Target Activation Testing in the U.S.
Theralink® Technologies Appoints Thomas Chilcott as Chief Financial Officer
Copyright © 2020 Theralink. All rights reserved.
We use cookies to improve your experience on our site. If you continue the use of this site then you accept our terms of use and privacy policy.Terms & Privacy